BR112023006274A2 - Proteína de fusão útil para vacinação contra rotavírus - Google Patents

Proteína de fusão útil para vacinação contra rotavírus

Info

Publication number
BR112023006274A2
BR112023006274A2 BR112023006274A BR112023006274A BR112023006274A2 BR 112023006274 A2 BR112023006274 A2 BR 112023006274A2 BR 112023006274 A BR112023006274 A BR 112023006274A BR 112023006274 A BR112023006274 A BR 112023006274A BR 112023006274 A2 BR112023006274 A2 BR 112023006274A2
Authority
BR
Brazil
Prior art keywords
fusion protein
rotavirus
vaccination against
fragment
protein useful
Prior art date
Application number
BR112023006274A
Other languages
English (en)
Inventor
ANSTROM David
Rae Patterson Abby
Brian Haiwick Gregory
Scott JOHNSON Wesley
NICHOLSON Bryon
Martin Vaughn Eric
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of BR112023006274A2 publication Critical patent/BR112023006274A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROTEÍNA DE FUSÃO ÚTIL PARA VACINAÇÃO CONTRA ROTAVÍRUS. A presente invenção refere-se a polipeptídeos construídos de forma recombinante úteis para preparar vacinas, em particular, para reduzir um ou mais de sinais clínicos causados por uma infecção por rotavírus. Mais especificamente, a presente invenção é dirigida a uma proteína de fusão c ompreendendo na direção N- para C-terminal (i) um fragmento imunogênico de uma proteína VP8 do rotavírus e (ii) um fragmento Fc de imunoglobulina tal como, por exemplo, um fragmento Fc de IgG, em que a referida proteína de fusão é utilizável em um método de redução de um ou mais de sinais clínicos, mortalidade ou excreção fecal causada(os) por uma infecção por rotavírus em suínos.
BR112023006274A 2020-10-05 2021-10-04 Proteína de fusão útil para vacinação contra rotavírus BR112023006274A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20200161 2020-10-05
PCT/US2021/071701 WO2022076979A1 (en) 2020-10-05 2021-10-04 Fusion protein useful for vaccination against rotavirus

Publications (1)

Publication Number Publication Date
BR112023006274A2 true BR112023006274A2 (pt) 2023-05-09

Family

ID=72752390

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006274A BR112023006274A2 (pt) 2020-10-05 2021-10-04 Proteína de fusão útil para vacinação contra rotavírus

Country Status (13)

Country Link
US (1) US20220160866A1 (pt)
EP (1) EP4225776A1 (pt)
JP (1) JP2023544396A (pt)
KR (1) KR20230082653A (pt)
CN (1) CN116438195A (pt)
AU (1) AU2021356630A1 (pt)
BR (1) BR112023006274A2 (pt)
CA (1) CA3195910A1 (pt)
CL (1) CL2023000836A1 (pt)
CO (1) CO2023003544A2 (pt)
MX (1) MX2023004006A (pt)
TW (1) TW202229314A (pt)
WO (1) WO2022076979A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240050555A1 (en) * 2022-04-05 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus
CN114875047A (zh) * 2022-05-27 2022-08-09 江苏三仪生物工程有限公司 一种优化的猪轮状病毒外衣壳蛋白vp4的重组表达及应用
CN114957489B (zh) * 2022-06-20 2023-11-21 甘肃省畜牧兽医研究所 一种猪轮状病毒重组蛋白及其应用
CN115873131A (zh) * 2022-12-13 2023-03-31 广州爱仁生物医药科技有限公司 一种病毒抗原检测试剂盒及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US920197A (en) 1906-04-25 1909-05-04 Benjamin Siegel Garment-display rack.
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1026253B2 (en) 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
DE69536091D1 (de) 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
DK0758397T3 (da) 1994-04-29 2005-10-10 Baxter Healthcare Sa Rekombinante poxvira med fremmede polynucleotider i essentielle regioner
WO1996029421A1 (en) 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
DE69740033D1 (de) 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6187319B1 (en) * 1998-06-01 2001-02-13 University Of Massachusetts Cross-protective rotavirus vaccine
US8675566B2 (en) 2009-09-17 2014-03-18 Digifonica (International) Limited Uninterrupted transmission of internet protocol transmissions during endpoint changes

Also Published As

Publication number Publication date
CA3195910A1 (en) 2022-04-14
CO2023003544A2 (es) 2023-06-30
JP2023544396A (ja) 2023-10-23
MX2023004006A (es) 2023-04-26
AU2021356630A1 (en) 2023-06-08
WO2022076979A1 (en) 2022-04-14
KR20230082653A (ko) 2023-06-08
CL2023000836A1 (es) 2023-12-01
TW202229314A (zh) 2022-08-01
CN116438195A (zh) 2023-07-14
US20220160866A1 (en) 2022-05-26
EP4225776A1 (en) 2023-08-16

Similar Documents

Publication Publication Date Title
BR112023006274A2 (pt) Proteína de fusão útil para vacinação contra rotavírus
PE20061398A1 (es) Vacuna de toxoide de c. perfringens alfa
Singh et al. A Plasmodium falciparum 48/45 single epitope R0. 6C subunit protein elicits high levels of transmission blocking antibodies
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
PE20240825A1 (es) Anticuerpos anti-c5 y metodos de uso
BR112015023105A8 (pt) construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo.
DK1968632T3 (da) Forbedret influenzavaccine
BR112016019525A2 (pt) construções de proteína uspa2 e seu uso
BR112015022617A2 (pt) polipeptídeo recombinante termoestável, composição imunogênica, vetor de expressão recombinante e uso de um polipeptídeo recombinante termoestável
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
RU2020119271A (ru) Вакцина для защиты от streptococcus suis
AU2010303568A1 (en) Immunopotentiator-linked oligomeric influenza immunogenic compositions
BR112017001966A2 (pt) ?método para produzir variantes com um fc com sialilação melhorada?
BR112016028418A2 (pt) composição de adjuvante, vacina, anticorpo agonista cd40 ou uma parte desse, composição farmacêutica, construto, célula, e, método de mapeamento de epítopo de um polipeptídeo
CL2021002727A1 (es) Vacuna con subunidades del vfpc
BR112021016272A2 (pt) Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
BR112017002496A2 (pt) agente de controle contra a síndrome reprodutiva e respiratória porcina
CN105408347A (zh) 寡聚流感免疫原性组合物
BR112016016103A2 (pt) Composição de antígenos micobacterianos
BR112015023738B8 (pt) Vacinas de nucleoproteina influenza
EA201690115A1 (ru) Комбинированные иммуногенные композиции
BR112015023402A2 (pt) Proteínas sintéticas de automontagem
MX349653B (es) Vacunógeno de ospc quimérico polivalente y antígeno de diagnóstico.
Xiong et al. A porcine reproductive and respiratory syndrome virus (PRRSV) vaccine candidate based on the fusion protein of PRRSV glycoprotein 5 and the Toll-like Receptor-5 agonist Salmonella Typhimurium FljB
BR112022011422A2 (pt) Imunógenos para vírus da caxumba e do sarampo e seus usos